Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mary M Mader

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Molecular Cancer Therapeutics|July 22, 2016
Characterization of LY3023414, a Novel PI3K/mTOR Dual Inhibitor Eliciting Transient Target Modulation to Impede Tumor GrowthMichele C Smith, Mary M Mader, James A Cook, et al.
ACS Medicinal Chemistry Letters|July 24, 2018
LLY-283, a Potent and Selective Inhibitor of Arginine Methyltransferase 5, PRMT5, with Antitumor ActivityZahid Q Bonday, Guillermo S Cortez, Michael J Grogan, et al.
Bioorganic & Medicinal Chemistry Letters|January 25, 2005
Acyl sulfonamide anti-proliferatives. Part 2: activity of heterocyclic sulfonamide derivativesMary M Mader, Chuan Shih, Eileen Considine, et al.
Journal of Medicinal Chemistry|April 9, 2026
Nanoscale Direct-to-Biology Optimization of Cdk2 InhibitorsJames L Douthwaite, Damian J Houde, Eneida Pardo, et al.
Journal of Medicinal Chemistry|February 16, 2021
A First-in-Class, Highly Selective and Cell-Active Allosteric Inhibitor of Protein Arginine Methyltransferase 6Yudao Shen, Fengling Li, Magdalena M Szewczyk, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 1, 2024
Discovery of lirafugratinib (RLY-4008), a highly selective irreversible small-molecule inhibitor of FGFR2Heike Schönherr, Pelin Ayaz, Alexander M Taylor, et al.
Journal of Medicinal Chemistry|October 16, 2004
Acyl sulfonamide anti-proliferatives: benzene substituent structure-activity relationships for a novel class of antitumor agentsKaren L Lobb, Philip A Hipskind, James A Aikins, et al.
Cancer Discovery|November 2, 2023
Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from HyperinsulinemiaAndreas Varkaris, Ermira Pazolli, Hakan Gunaydin, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Molecular Cancer Therapeutics|July 22, 2016
Characterization of LY3023414, a Novel PI3K/mTOR Dual Inhibitor Eliciting Transient Target Modulation to Impede Tumor GrowthMichele C Smith, Mary M Mader, James A Cook, et al.
ACS Medicinal Chemistry Letters|July 24, 2018
LLY-283, a Potent and Selective Inhibitor of Arginine Methyltransferase 5, PRMT5, with Antitumor ActivityZahid Q Bonday, Guillermo S Cortez, Michael J Grogan, et al.
Bioorganic & Medicinal Chemistry Letters|January 25, 2005
Acyl sulfonamide anti-proliferatives. Part 2: activity of heterocyclic sulfonamide derivativesMary M Mader, Chuan Shih, Eileen Considine, et al.
Journal of Medicinal Chemistry|April 9, 2026
Nanoscale Direct-to-Biology Optimization of Cdk2 InhibitorsJames L Douthwaite, Damian J Houde, Eneida Pardo, et al.
Journal of Medicinal Chemistry|February 16, 2021
A First-in-Class, Highly Selective and Cell-Active Allosteric Inhibitor of Protein Arginine Methyltransferase 6Yudao Shen, Fengling Li, Magdalena M Szewczyk, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 1, 2024
Discovery of lirafugratinib (RLY-4008), a highly selective irreversible small-molecule inhibitor of FGFR2Heike Schönherr, Pelin Ayaz, Alexander M Taylor, et al.
Journal of Medicinal Chemistry|October 16, 2004
Acyl sulfonamide anti-proliferatives: benzene substituent structure-activity relationships for a novel class of antitumor agentsKaren L Lobb, Philip A Hipskind, James A Aikins, et al.
Cancer Discovery|November 2, 2023
Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from HyperinsulinemiaAndreas Varkaris, Ermira Pazolli, Hakan Gunaydin, et al.
Pageof 2